bioAffinity Technologies (BIAF) Total Current Liabilities (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Total Current Liabilities data on file, last reported at $3.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $3.2 million, down 6.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (down 6.75% YoY), and the FY2025 annual result was $2.9 million, down 6.4% from the prior year.
• Total Current Liabilities grew to $3.2 million in Q1 2026 per BIAF's latest filing, from $2.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $3.4 million in Q1 2025 and troughed at $775151.0 in Q2 2023.
• A 5-year average of $2.2 million and a median of $2.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities tumbled 91.27% in 2022, then soared 200.11% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $1.1 million in 2022, then surged by 97.41% to $2.2 million in 2023, then soared by 38.13% to $3.1 million in 2024, then slipped by 6.4% to $2.9 million in 2025, then gained by 9.59% to $3.2 million in 2026.
• Business Quant data shows BIAF's Total Current Liabilities at $3.2 million in Q1 2026, $2.9 million in Q4 2025, and $2.4 million in Q3 2025.